Agomab Therapeutics (AGMB) said Thursday that it priced its initial public offering of 12.5 million American depositary shares at $16 per ADS, for total proceeds of $200 million.
The company granted the underwriters a 30-day option to acquire up to about 1.9 million ADSs.
Agomab expects to close the IPO on Feb. 9 and said its ADSs are set to start trading on the Nasdaq Global Select Market on Friday under the ticker "AGMB."